Editorial - (2021) Volume 11, Issue 6
Received: 16-Jun-2021
Published:
26-Jun-2021
, DOI: 10.37421/2161-105X.2021.11.547
Citation: Pramod A. "A Brief Note on Paediatric Pulmonary Hypertension." J Pulm Respir Med 11 (2021): 547.
Copyright: 2021 Pramod A. This is an open-access article distributed under the terms of the creative commons attribution license which permits unrestricted
use, distribution and reproduction in any medium, provided the original author and source are credited.
Pulmonary hypertension (PH), or high blood pressure in the lungs, is linked to a high rate of morbidity and mortality in children, and it can be caused by a range of factors. Several pulmonary arterial hypertension-targeted medicines are now available to lower pulmonary artery pressure and improve outcomes, but there is still no cure for pulmonary arterial hypertension. This review includes a discussion of some of the most common causes of PH in children, as well as an update on the most recent evidence on the evaluation and management of children with PH. In paediatrics, the available evidence for distinct classes of PH-targeted treatments is examined. A vast range of acute and chronic respiratory problems afflict children. The number of children with respiratory disease, as well as the complexity of disease pathophysiology and care demands on paediatric pulmonologists, is on the rise. Even though the number of board-certified paediatric pulmonologists is steadily increasing, major portions of the country remain underserved, and there is concern about a potential manpower shortage. There are a variety of explanations for these worries. To address these concerns, the Pediatric Pulmonology Division Directors Association and the Pediatric Pulmonary Training Directors Association collaborated. Paediatric pulmonary arterial hypertension (PAH) has many of the same symptoms as adult pulmonary arterial hypertension, but it is also associated with several additional illnesses and problems that necessitate special treatment. The Paediatric Task Force of the 6th World Symposium on Pulmonary Hypertension delivered this article, which highlights recent breakthroughs, current issues, and distinct methods for the care of children with PAH. Updates on the prior classification system's efficacy in reflecting paediatric-specific aetiologies and approaches to medical and interventional therapy are offered.
Pulmonary & Respiratory Medicine received 1690 citations as per Google Scholar report